Research & Development

R&D at PMI

Developing products that may have the potential to reduce the risks of smoking-related diseases is one of our top priorities. To address this complex challenge, our team includes scientists with expertise across a range of disciplines including biology, chemistry, engineering, mathematics and computing.

 
Learn more

Disease Mechanisms

We are working to understand the underlying mechanisms of the diseases caused by smoking. Today, advanced technologies may allow us to use existing data to explore how tobacco related diseases develop in the human body and identify gaps in knowledge.
 

 

Learn more

Assessing Risk Reduction

Assessing Risk Reduction

To develop methods to assess whether a product is likely to reduce the risk of smoking-related diseases, we plan to  use the strengths of classical scientific methods including pre-clinical and clinical studies,  In the future we plan to combine these with systems biology, state-of-the-art computational science, and disease modeling.

More than 5,000 smoke constituents have been identified in tobacco smoke, with approximately 100 identified as likely causes of smoking-related disease.

Cookie Consent